Virginia is currently home to 1821 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Cardiac Sarcoidosis Randomized Trial
NCT03593759
Recruiting
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than sta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Cardiac Sarcoidosis, Sarcoidosis
Register for Updates
A Study of ADRX-0405 in Subjects with Select Advanced Solid Tumors
NCT06710379
Recruiting
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Solid Tumors
Register for Updates
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
NCT05270213
Recruiting
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with checkpoint blo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: NEXT Virigina, Fairfax, Virginia
Conditions: Advanced Cancer
Register for Updates
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
NCT05230459
Recruiting
The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/26/2024
Locations: VCU, Richmond, Virginia
Conditions: Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I, Muscular Dystrophy, LGMD2, LGMD, FKRP, FKRP Mutation, Fukutin Related Protein
Register for Updates
PAS-004 in Patients With Advanced Solid Tumors
NCT06299839
Recruiting
The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: * How well participants are able tolerate different doses of PAS-004, and * What side effects PAS-004 might have. Study participants will have regular visits to the study doctor and be asked to have tests and exams done to check on their health... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: NEXT Oncology, Fairfax, Virginia
Conditions: RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
Register for Updates
Feasibility and Acceptability of Using Weighted Blankets to Prevent and /or Mitigate Delirium
NCT06161480
Recruiting
The use of weighted blankets to avert or alleviate Delirium in Adult ICU patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: VCU Health Systems, Richmond, Virginia
Conditions: Delirium
Register for Updates
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
NCT04916210
Recruiting
The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a "stroke... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment
Register for Updates
Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures At High Risk of Infection: TOBRA
NCT04597008
Recruiting
The overall objective is to compare the effect of Vancomycin and Tobramycin powder combined (treatment) to Vancomycin powder (control) in the reduction of post-fixation infections of tibial plateau and tibial pilon fractures at high risk of infection (collectively considered the "study injuries").
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/25/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Post Operative Surgical Site Infection
Register for Updates
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Cutaneous Melanoma, Stage II
Register for Updates
Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System
NCT06157567
Recruiting
This is a non-randomized, multi-center, open-label clinical trial evaluating clinical feasibility treatments with the Profound Matrix system.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/22/2024
Locations: Gerrish MedEsthetics, Vienna, Virginia
Conditions: Skin Laxity, Wrinkle, Skin Condition
Register for Updates
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Research Site, Charlottesville, Virginia
Conditions: Breast Cancer
Register for Updates
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964
Recruiting
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. * Were confirmed to have AD at least 6 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Virginia Dermatology and Skin Cancer Center, Norfolk, Virginia
Conditions: Atopic Dermatitis
Register for Updates